Literature DB >> 2307935

Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies.

J D Baumgartner1, D Heumann, J Gerain, P Weinbreck, G E Grau, M P Glauser.   

Abstract

Two-core LPS antibodies, the rabbit J5 polyclonal antiserum and the human anti-lipid A IgM mAb HA-1A, did not improve the survival of mice challenged with E. coli O111 or P. aeruginosa 3, or with the LPS extracted from them, and did not decrease the incidence of Shwartzman reactions in rabbits challenged with O111 LPS. In contrast, O side chain-specific rabbit antisera were protective in these models. The protection afforded by O side chain-specific antisera against endotoxin lethality was associated with decreased LPS-induced serum TNF and IL-6 levels, whereas core LPS antibodies had no effect on TNF or IL-6 levels. The absence of reduction of LPS-induced cytokines levels by core LPS antibodies suggests that these antibodies are not able to prevent the interactions between LPS and target cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2307935      PMCID: PMC2187790          DOI: 10.1084/jem.171.3.889

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  21 in total

1.  Multiple actions of interleukin 6 within a cytokine network.

Authors:  G G Wong; S C Clark
Journal:  Immunol Today       Date:  1988-05

2.  Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man.

Authors:  Y Fong; L L Moldawer; M Marano; H Wei; S B Tatter; R H Clarick; U Santhanam; D Sherris; L T May; P B Sehgal
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

3.  A proposed mechanism for natural immunity to enterobacterial pathogens.

Authors:  L Chedid; M Parant; F Parant; F Boyer
Journal:  J Immunol       Date:  1968-02       Impact factor: 5.422

4.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

5.  Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura.

Authors:  E Girardin; G E Grau; J M Dayer; P Roux-Lombard; P H Lambert
Journal:  N Engl J Med       Date:  1988-08-18       Impact factor: 91.245

6.  Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.

Authors:  J C Mathison; E Wolfson; R J Ulevitch
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

7.  Lipopolysaccharide (LPS)-reactive monoclonal antibodies fail to inhibit LPS-induced tumor necrosis factor secretion by mouse-derived macrophages.

Authors:  J K Chia; M Pollack; G Guelde; N L Koles; M Miller; M E Evans
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

8.  The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome.

Authors:  A Waage; P Brandtzaeg; A Halstensen; P Kierulf; T Espevik
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

9.  Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice.

Authors:  V Lehmann; M A Freudenberg; C Galanos
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

10.  Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma.

Authors:  P Brouckaert; D R Spriggs; G Demetri; D W Kufe; W Fiers
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

View more
  36 in total

Review 1.  Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.

Authors:  R Salomão; O Rigato; A C Pignatari; M A Freudenberg; C Galanos
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

2.  Characterization of the epitope specificity of murine monoclonal antibodies directed against lipid A.

Authors:  H M Kuhn; L Brade; B J Appelmelk; S Kusumoto; E T Rietschel; H Brade
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

Review 3.  Back to the future: antibody-based strategies for the treatment of infectious diseases.

Authors:  H Barbaros Oral; Cüneyt Ozakin; Cezmi A Akdiş
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

Review 4.  Monoclonal anti-endotoxin antibodies for the treatment of gram-negative bacteremia and septic shock.

Authors:  J D Baumgartner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

5.  Monoclonal antibodies in sepsis and septic shock.

Authors:  C J Hinds
Journal:  BMJ       Date:  1992-01-18

Review 6.  The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin.

Authors:  Lara Marks
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 7.  Sepsis management and antiendotoxin therapy after nebacumab. A reappraisal.

Authors:  J C Hurley
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

8.  alpha-GlcNAc-1-->2-alpha-glc, the Salmonella homologue of a conserved lipopolysaccharide motif in the Enterobacteriaceae, elicits broadly cross-reactive antibodies.

Authors:  N A Nnalue
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Pollack; N L Koles; M J Preston; B J Brown; G B Pier
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

10.  Effect of imipenem on monoclonal antibody-mediated protection against Escherichia coli O18K5.

Authors:  H Frasa; B Benaissa-Trouw; L Tavares; K van Kessel; W Hustinx; J Schellekens; K Kraaijeveld; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.